Simple, efficient workflow producing clinically meaningful answers.
TOMA has commercially launched TOMA OS-SeqTM Cancer Assay to help laboratories and researchers uncover clinically meaningful genomic changes in tumors, including many missed by other methods.
With an exclusive license to the oligo selective sequencing (OS-Seq) technology invented at Stanford University, TOMA has developed a fast, simple and efficient way to comprehensively analyze all types of tumor samples – even those with limited volume and poor quality.
A team of renowned industry specialists is leading the product development, commercialization and regulatory pathways to bring these products to laboratories, hospital systems and research institutions around the world.
Find Cancer Mutations Using TOMA OS-SeqTM Technology
Breakthrough targeted sequencing technology enables analysis of DNA from archival FFPE tissue and low quantities such as fine needle aspirations, core needle biopsies or plasma (coming soon).
Precision Medicine Webinar Series
Learn the latest in Cancer Genomics